Open Access
Issue
Published:
28 January 2021
Beta-blocker therapy in elderly patients with renal dysfunction and heart failure
),
Download citation
590
Views
44
Downloads
0
Crossref
2
WoS
2
Scopus
1
CSCD
To assess the role of beta-blockers (BB) in patients with chronic kidney disease (CKD) aged ≥ 75 years.
From January 2008 to July 2014, we included 390 consecutive patients ≥ 75 years of age with ejection fraction ≤ 35% and glomerular filtration rate (GFR) ≤ 60 mL/min per 1.73 m2. We analyzed the relationship between treatment with BB and mortality or cardiovascular events. The mean age of our population was 82.6 ± 4.1 years. Mean ejection fraction was 27.9% ± 6.5%. GFR was 60−45 mL/min per 1.73 m2 in 50.3% of patients, 45−30 mL/min per 1.73 m2 in 37.4%, and < 30 mL/min per 1.73 m2 in 12.3%. At the conclusion of follow-up, 67.4% of patients were receiving BB. The median follow-up was 28.04 (IR: 19.41−36.67) months. During the study period, 211 patients (54.1%) died and 257 (65.9%) had a major cardiovascular event (death or hospitalization for heart failure). BB use was significantly associated with a reduced risk of death (HR = 0.51, 95% CI: 0.35−0.74; P < 0.001). Patients receiving BB consistently showed a reduced risk of death across the different stages of CKD: stage IIIa (GFR = 30−45 mL/min per 1.73 m2; HR = 0.47, 95% CI: 0.26−0.86, P < 0.0001), stage IIIb (GFR 30−45 mL/min per 1.73 m2; HR = 0.55, 95% CI: 0.26−1.06, P = 0.007), and stages IV and V (GFR < 30 mL/min per 1.73 m2; HR = 0.29, 95% CI: 0.11−0.76; P = 0.047).
The use of BB in elderly patients with HFrEF and renal impairment was associated with a better prognosis. Use of BB should be encouraged when possible.
menu
Beta-blocker therapy in elderly patients with renal dysfunction and heart failure
),
Abstract
To assess the role of beta-blockers (BB) in patients with chronic kidney disease (CKD) aged ≥ 75 years.
From January 2008 to July 2014, we included 390 consecutive patients ≥ 75 years of age with ejection fraction ≤ 35% and glomerular filtration rate (GFR) ≤ 60 mL/min per 1.73 m2. We analyzed the relationship between treatment with BB and mortality or cardiovascular events. The mean age of our population was 82.6 ± 4.1 years. Mean ejection fraction was 27.9% ± 6.5%. GFR was 60−45 mL/min per 1.73 m2 in 50.3% of patients, 45−30 mL/min per 1.73 m2 in 37.4%, and < 30 mL/min per 1.73 m2 in 12.3%. At the conclusion of follow-up, 67.4% of patients were receiving BB. The median follow-up was 28.04 (IR: 19.41−36.67) months. During the study period, 211 patients (54.1%) died and 257 (65.9%) had a major cardiovascular event (death or hospitalization for heart failure). BB use was significantly associated with a reduced risk of death (HR = 0.51, 95% CI: 0.35−0.74; P < 0.001). Patients receiving BB consistently showed a reduced risk of death across the different stages of CKD: stage IIIa (GFR = 30−45 mL/min per 1.73 m2; HR = 0.47, 95% CI: 0.26−0.86, P < 0.0001), stage IIIb (GFR 30−45 mL/min per 1.73 m2; HR = 0.55, 95% CI: 0.26−1.06, P = 0.007), and stages IV and V (GFR < 30 mL/min per 1.73 m2; HR = 0.29, 95% CI: 0.11−0.76; P = 0.047).
The use of BB in elderly patients with HFrEF and renal impairment was associated with a better prognosis. Use of BB should be encouraged when possible.
References(33)
Gheorghiade M, Sopko G, Luca L De, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006; 114: 1202−1013.
Khatibzadeh S, Farzadfar F, Oliver J, et al. Worldwide risk factors for heart failure: A systematic review and pooled analysis. Int J Cardiol 2013; 168: 1186−1194.
Martinez-Milla J, Raposeiras-Roubin S, Pascual-Figal DA, Ibanez B. Role of Beta-blockers in Cardiovascular Disease in 2019. Rev Esp Cardiol (Engl Ed) 2019; 72: 844−852.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129−2200.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol 2013; 62: e147−e239.
Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004; 148: 971−978.
Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf 1996; 15: 200−211.
Martinez-Milla J, Garcia MC, Urquia MT, et al. Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study. Drugs Aging 2019; 36: 1123−1131.
Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009; 30: 478−486.
Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162: 1682−1688.
Patel P, White DL, Deswal A. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J 2007; 153: 515−522.
Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 2007; 71: 449−454.
Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007; 18: 1307−1315.
Vidan MT, Blaya-Novakova V, Sanchez E, et al. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail 2016; 18: 869−875.
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137−1146.
Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184−192.
Lainscak M, Duengen H-D, Anker SD. Beta-blockers in elderly patients with heart failure ready for prime time? J Am Coll Cardiol 2009; 54: 2202.
Franco Pelaez JA, Cortes Garcia M, Romero Daza AM, et al. Relationship between different doses of beta-blockers and prognosis in elderly patients with reduced ejection fraction. Int J Cardiol 2016; 220: 219−225.
Lofman I, Szummer K, Hagerman I, et al. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Hear 2016; 3: e000324.
Damman K, Valente MAE, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014; 35: 455−469.
Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of blockers in patients with heart failure and reduced ejection fraction: Network meta-analysis. BMJ 2013; 346: 1−10.
Hawwa N, Schreiber MJJ, Tang WHW. Pharmacologic management of chronic reno-cardiac syndrome. Curr Heart Fail Rep 2013; 10: 54−62.
Heywood JT, Fonarow GC, Yancy CW, et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. Am J Cardiol 2010; 105: 1140−1146.
Damman K, Tang WHW, Felker GM, et al. Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. J Am Coll Cardiol 2014; 63: 853−871.
Ghali JK, Wikstrand J, Van Veldhuisen DJ, et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). J Card Fail 2009; 15: 310−318.
Castagno D, Jhund PS, McMurray JJ V, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010; 12: 607−616.
Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009; 11: 872−880.
Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail 2011; 4: 18−26.
Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438−1444.
Kotecha D, Gill SK, Flather MD, et al. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. J Am Coll Cardiol 2019; 74: 2893−2904.
Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 2001; 37: 1191−1200.
McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002; 144: 226−232.
Publication history
Copyright
Acknowledgements
To Oliver Shaw for editing the manuscript for aspects related to English language usage and style.
FEEDBACK 
TOP